Select An Issue
Selected Issue:
Issue 5
8th
March 2010
C&I Magazine
C&I MagazineThe leading source of news and opinion in the arena of chemical technology
Cover Story
R&D budgets are holding up in some companies but how can the benefits
be measured? Neil Eisberg reports
News
Emma Dorey,
08/03/2010
Drug giant AstraZeneca has
signed a $1.3bn deal to develop
and commercialise a drug to treat
rheumatoid arthritis.
Cath O’Driscoll,
08/03/2010
US plans to curb emissions of
greenhouse gases have come under
fire in recent weeks after a spate of
announcements from industry groups,
oil majors and three US states.
Features
Chris Frampton,
08/03/2010
Formulating drugs as cocrystals could overcome the solubility
problems hampering the development of some active pharma
ingredients, reports Chris Frampton
Lou Reade,
08/03/2010
Textiles that incorporate biosensors, or act as heat sinks, or mimic human bone are
racing towards commercialisation. Lou Reade reports
Editor's Blog
Davos debates
Agree or disagree? Post your views below
In the Swiss winter resort of Davos last week, there appeared to be two groups of delegates at the World Economic Forum (WEF), Europe and the rest of world with two distinct outlooks: optimism in most of the world and pessimism from European attendees. The picture might have been different if the delegates had known that the next news about the world economy was likely to be less than optimistic, but again much of this week’s bad news has been from Europe.
Despite the hand wringing about the economic outlook, there was some ‘good news’ in terms of health initiatives, from the likes of the Bill and Melinda Gates Foundation amongst others, and there was still room for optimism regarding the outlook for feeding the world's ever-growing population.